The development of a T cell receptor excision circle (TREC) assay utilizing dried blood spots (DBS) made possible universal newborn screening (NBS) for severe combined immunodeficiency (SCID) as a public health measure. Upon being flagged by an abnormal screening test in a SCID screening program, an infant can receive further diagnostic testing for SCID in the neonatal period, prior to onset of infectious complications, to permit immediate institution of protective measures and definitive, life-saving treatment to establish a functional immune system. SCID screening is now the accepted standard of care in state public health departments across the United States, and it is being adopted in many countries. It has proven effective, with infants having this otherwise inapparent but serious, rare disorder achieving survival and immune reconstitution. In addition to bringing to attention infants with the primary screening target diseases, typical SCID and leaky SCID (due to hypomorphic mutations in known SCID genes), the NBS assay for insufficient TRECs in DBS also reveals infants with non-SCID T lymphopenic conditions. Experience has accumulated regarding the range and limitations of diagnoses of newborns with low TRECs and low T cells. Previously unknown immune defects have been discovered, as well as conditions not formerly recognized to have low T cells in the neonatal period.
| INTRODUC TI ON
Severe combined immunodeficiency (SCID) is the term used to describe at least 20 known, and additional unknown, rare genetic disorders in which both T and B cell immunity, the components of the and X-linked SCID, with Artemis-deficient SCID also being tested in a clinical trial. 1, 2, [4] [5] [6] [7] Best outcomes are achieved if infants are treated early to avoid infectious complications, as documented by single center reports 8 and by retrospective and prospective multicenter studies from the Immune Deficiency Foundation 9 and Primary
Immune Deficiency Treatment Consortium (PIDTC). [5] [6] [7] Because SCID is rare and affected infants appear healthy at birth, and the majority of cases have no recognized positive family history, population-based newborn screening (NBS) was turned to as a strategy to identify infants with SCID sufficiently early in life to provide treatment before the onset of infectious complications. 2, 8, 9 Unlike traditional one-on-one diagnostic evaluations of patients, basic immunological research or advancement of new therapies in clinical trials, screening presents a new paradigm for immunological advancement from which unparalleled insights have been gained.
However, because screening is imposed upon an entire population with the goal of advancing public health, it is important to appreciate the differences between population-based screening programs versus clinical care or consented research. In this track, very few options were available for treating patients until recently. For decades after the first recognition that genetic factors could lead to susceptibility to infections or to autoimmune or inflammatory conditions, the only treatments available addressed these complications, rather than the underlying disease processes themselves. Nonetheless, such breakthroughs as antibiotics were lifesaving, for example changing the original "fatal granulomatous disease" 12 due to absence of the respiratory burst leading oxidative intracellular killing of S. aureus and other infections to "chronic granulomatous disease." 13 Similarly, steroids were the primary treatment for autoimmunity, despite unwanted side effects, not the least of which was making already immune deficient patients even more susceptible to infections.
| E VOLUTI ON OF THE FIELD OF PRIMARY IMMUNODEFICIEN C Y
Certain primary immunodeficiencies have been proven amenable to treatments that bypass the genetic defect in a generic manner. These treatments include administration of immunoglobulin G F I G U R E 
| SCREENING FOR SCID A S A PUB LIC HE ALTH ME A SURE
Screening an entire population for primary immunodeficiency is a radical departure from previous scientific and medical paradigms in this field ( Figure 1, lower liquid blood samples to determine T cell numbers was also proposed as a screening method, but the cost of obtaining and running a liquid blood sample for every infant rather than using the existing DBS sample to rule out problems in the large majority would be prohibitive.
| J US TIFI C ATI ON FOR NE WBORN SCREENING FOR SCID WITH THE TREC TE S T
Protein assays for T cell specific markers such as CD3 chains were also tried, but had insufficient reproducibility due to the low amount of protein that could be recovered from DBS samples. 
| IMPLEMENTATI ON OF SCID NBS IN THE USA
Following an evidence-based review and pilot TREC screening programs in Wisconsin, Massachusetts and the Navajo Reservation 
| FIND ING S FROM SCID NE WBORN SCREENING IN C ALIFORNIA

| California SCID Population and Methods
Lack of standardized practices has complicated analysis of aggregate performance data across programs, so available data from California, an ethnically diverse state with the highest number of births, are summarized here. 37 The experience of California alone is larger than the previously generated data from 11 pooled screening programs, 
| SCID found by NBS
Of the 50 infants with an immuno-phenotype of SCID, the genotype distribution is shown in Figure 3 . One infant born to a foreign visitor left the USA before receiving any further care. The others were healthy at diagnosis at a mean of 21 days of age (range 0-40 days), except for two who had sought medical attention for infection or rashes and one preterm infant with feeding intolerance, bronchiolitis, and leukopenia. 40 Only two infants identified by SCID NBS were known by their doctors to be at risk for SCID due to a positive family history, while seven others in retrospect had older affected relatives with SCID, and one had a sibling who had died of infantile pneumonia consistent with SCID.
Of the 49 evaluable patients who were treated 46 survived (94%) after receiving allogeneic HCT, autologous corrected cell GT, or ERT (Table 1) 
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| Missed cases of leaky SCID that presented after the newborn period
Two cases of SCID were discovered to have been missed by NBS.
One infant, who presented at age 7 months with Pneumocystis pneumonia, had the known, recurrent, hypomorphic X-linked IL2RG mutation Arg222Cys. 42 His delayed-onset, leaky SCID was successfully treated with a conditioned HCT from a matched unrelated donor. The other was a delayed-onset case of incomplete ADA-deficiency, diagnosed at 23 months of age after repeated otitis and hospitalization for pneumonia. 43 This child was successfully treated with GT. Both infants had newborn DBS TREC numbers well above the cut-off for follow-up testing. Their mutations were sufficiently leaky to allow some T cell maturation with normal TREC production during the neonatal period, but by the time of diagnosis T cell insufficiency had led to infections as well as low T cell numbers and TRECs. Importantly, raising the TREC cutoff in the California SCID screening program would not have helped to identify either of these cases by NBS. They illustrate that SCID, like most single gene disorders, has a broad spectrum of mutations and phenotypic presentations that rarely (in fewer than one in a million births in the California experience) can have false negative both TREC NBS.
| Non-SCID T-cell lymphopenia
Infants with non-SCID TCL were classified as listed in Table 2 and detailed in Figure 4 . While most of these 72 cases received a definitive diagnosis in the neonatal period, 22 required further testing over 3-18 months to establish a diagnosis ( Figure 4 , gray shading). The most frequent non-SCID TCL conditions were congenital syndromes ( Figure 4 , Table 2 ). Six additional infants with TA B L E 1 Genotypes, treatments, and outcome of 49 severe combined immunodeficiency (SCID) cases identified by newborn screening Rising alpha-fetoprotein levels after age 6 months or sequencing panels of genes or exomes led to identification of homozygous or compound heterozygous deleterious mutations in the ATM gene. 47 One infant with AT developed infections requiring IgG infusions during his first year. One infant with CHARGE syndrome was considered for thymus transplantation, but died of respiratory failure. Single patients with very rare conditions constituted the remainder of cases with syndromes, including one with a novel short-limbed immuno-skeletal dysplasia in whom whole exome sequencing revealed EXTL3 deficiency 48 and one with RAC2 mutation as described in a single previous case. 49 Secondary TCL in 25 cases (Figure 4 ) resolved to normal once excess T-cell losses or suppression of T-cell maturation had been reversed. T-cell losses were associated with vascular leakage, chylothorax, and intestinal atresia or gastroschisis; while two infants TA B L E 2 Diagnoses and mortality of 72 infants with T-cell lymphopenia found by SCID newborn screening who had syndromes and non-SCID primary immunodeficiency, including cases initially classified as idiopathic | 249 PUCK had T-cell suppression due to in utero exposure to maternal medications, fingolimod and azathioprine, respectively, and one infant had a thymic teratoma, with T cells normalizing after it was resected.
Self-resolving TCL was also associated with preterm birth, generally affecting infants born at or before 32 weeks' gestation.
Idiopathic TCL included cases for which an underlying condition could not be determined, even after immunologic evaluation and in many instances sequencing of gene panels or whole exomes or genomes. Of the 33 cases with idiopathic TCL 13 resolved or improved while 13 were persistent and six were lost to follow-up.
| LE SSON S FROM SCID NE WBORN SCREENING
| Anticipated outcome
T cell receptor excision circle screening for SCID has established the feasibility and utility of DNA-based, high-throughput screening, which, like tandem mass spectrometry, has already proven adaptable to additional conditions, including SMA as approved in July,
2018, for addition to the Recommended Uniform Screening Panel.
31
As expected, TRECs have now been shown to be a highly specific and sensitive biomarker for the phenotype of T cell insufficiency, regardless of underlying genotype. Therefore, the California program based on screening newborns with the TREC test to identify and diagnose SCID has facilitated identification in presymptomatic infants with known and unknown SCID defects, permitting timely treatment with excellent survival. at UCSF and appears promising as well. 51 Based on our observed genotype frequencies for SCID (Figure 3) , around half of all infants with SCID may be eligible for GT in the near future. Experimental thymus transplantation has also been successful in selected cases of DiGeorge thymic insufficiency, but is not widely available. [44] [45] [46] Integrating lymphocyte phenotyping by flow cytometry as a fol- 
| Unanticipated findings
Population based, unbiased NBS with TRECs has also revealed findings that were not anticipated. The overall incidence of SCID, 1/65 000 births (95% CI 1/51 000-1/90 000) in California, is higher than was estimated prior to screening. 4, 52 or to present to medical attention later in infancy or childhood.
Although exceptionally rare, missed cases of leaky, late-onset SCID have now appeared, necessitating vigilance on the part of pediatricians and immunologists to consider T cell deficiencies in children presenting with frequent or opportunistic infections.
Discovery of TCL at birth in ataxia telangiectasia was a surprise, as without NBS this disease was formerly diagnosed only after the appearance of neurologic manifestations, ocular telangiectasias or frequent infections in childhood. 47 Trisomy 21, CLOVES syndrome, and RAC2 deficiency were not associated with newborn TCL prior to NBS for SCID.
Similarly, the original concept was that NBS could eliminate in- 
| CON CLUS ION
The combination of relative ease of implementation and importance supports the rapid adoption of TREC screening for SCID that has 
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